NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
ORIC Pharmaceuticals reported financial results and operational updates for Q4 2020.
ORIC Pharmaceuticals reported its Q4 and full-year 2020 financial results, highlighting the progress of its pipeline, team expansion, and strengthened balance sheet. The company's lead program, ORIC-101, is on track for initial data readouts in 2021, and three IND/CTA filings are expected for ORIC-533, -944, and -114. With $293.6 million in cash, cash equivalents, and investments, ORIC expects to fund operations into the second half of 2023.
- ORIC-101 is on track for two initial data readouts in 2021.
- Three IND/CTA filings for ORIC-533, -944, and -114 are expected in 2021.
- The company completed the Part I dose escalation portion of ORIC-101 in combination with nab-paclitaxel and enzalutamide.
- Cash, cash equivalents, and investments of $293.6 million are expected to fund current operations into the second half of 2023.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
ORIC anticipates several milestones in 2021, including data reports and IND/CTA filings.
Tailwinds
- Report interim safety, efficacy, and translational data from ongoing combination trial with nab-paclitaxel in the first half of 2021 for ORIC-101
- Report interim safety, efficacy, and translational data from ongoing combination trial with enzalutamide in the second half of 2021 for ORIC-101
- File an IND in the first half of 2021 for ORIC-533
- File an IND in the second half of 2021 for ORIC-944
- File a CTA in the second half of 2021 for ORIC-114
Headwinds
- Risks associated with discovering, developing, and commercializing drugs.
- Potential for clinical trials to differ from preclinical results.
- Negative impacts of the COVID-19 pandemic on operations.
- Risk of termination of license agreements.
- Reliance on third parties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro